Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CT45 – A key to long-term survival in ovarian cancer

21.09.2018

The diagnosis of ovarian cancer is still comparable to a death sentence. Only one in six patients survives more than 10 years after diagnosis. In a new study, an international research team from Germany, the USA, and Denmark, identified a molecular mechanism that is linked to patient long-term survival for those roughly 20% of the patients. By proteomic analysis, the protein CT45 was identified as a novel prognostic cancer cell marker. The authors further showed that the protein itself increases cancer cell death after platinum chemotherapy and activates the patient’s immune system. This work will be published in the renowned scientific journal Cell.

Ovarian Cancer


The protein CT45 seems one key for patient long term survival in ovarian cancer. The protein was discovered by analyzing tissue samples of cancer patients using Mass Spectrometry.

Illustration: Monika Krause © MPI of Biochemistry

Ovarian cancer is a very aggressive disease. Only every sixth patient survives more than 10 years after the first diagnosis. The majority of patients succumb to the disease within the first two years, which is mainly due to late detection of the disease when the tumor has already spread from the ovaries to the surrounding organs in the abdomen. Standard treatment involves surgical debulking followed by platinum-based chemotherapy.

“Although, for the majority of patients, this typically leads to an immediate response to therapy and reduction of tumor mass, the therapeutic effects are rarely permanent”, explains Prof. Dr. Ernst Lengyel from the University of Chicago, a world-leading gynecological oncologist. With over 42,000 deaths per year, ovarian cancer is the deadliest gynecologic malignancy in Europe.

Cause analysis

Scientists from the Max Planck Institute (MPI) of Biochemistry in Martinsried, Munich, have now in collaboration with researchers from Chicago and Copenhagen set out to elucidate the molecular basis for patient long-term survival.

"Only if we understand the molecular causes and differences between patients who respond well or poorly to therapy, will we improve the treatment of ovarian cancer in the clinic, and also pave the way for more personalized treatment options in the future" explains Lengyel, who initiated the study together with Prof. Dr. Matthias Mann, a pioneer and leading scientist in the field of mass spectrometry based proteomics. Mann is director at the MPI of Biochemistry and head of the department "Proteomics and Signal Transduction".

The DNA within our cells contains the instruction how to assemble proteins, the molecular machines that form the main players of most biological processes such as for metabolism or cellular signaling. In recent years, Mann and his team has developed and refined the technology of mass spectrometry for protein analysis to be for clinical use. "Using mass spectrometry, we can identify for the first time almost all of the proteins, the proteome, in the tumor tissue of the patients," says Mann. "Our highly sensitive methods now enable profiling thousands of proteins simultaneously, allowing us to search for the proteins that are critical to the disease by comparing the tissue samples," Prof. Mann continues.

CT45 influences long-term survival

For their analysis, the researchers used archived biobank material from the University of Chicago collected over many years, most of which originated from the initial operation of the patients. "This way, we can look back to the past in a way because we know exactly how the patient reacted to chemotherapy," says Dr. Fabian Coscia, first-author of the study and a Ph.D. student with Dr. Mann and now a postdoctoral fellow in Copenhagen.

With the help of mass spectrometry, the researchers discovered a protein called CT45, completely unknown till then, which was significantly increased in long-term survivors. Subsequent tests in the laboratory have confirmed the CT45 findings. When cancer cells produced the protein in cell culture, cells died much faster from standard chemotherapy.

CT45 a suicide gene?

But why does the cancer produce the protein CT45 if it promotes its own killing after chemotherapy? "The simple answer to this is that the cancer does not ‘know’ that it will be treated with platinum based chemotherapy" explains Coscia. "The samples we analyzed with proteomics were taken before chemotherapy. An adaptation of the tumor to the treatment has not yet taken place. We made similar observations in laboratory studies with isolated ovarian cancer cells."

Healthy cells normally only produce proteins that are needed for their specific tasks, for example, tasks typical for ovarian function. Although the blueprint for proteins, DNA, is the same in all cells, most of the protein assembly instructions are biochemically sealed. This means that only the ovary-specific "program", i.e. DNA, can be accessed. However, once a cell transforms and becomes a cancerous cell, it can lose its seal, the so-called methylation, and often proteins such as CT45 are then produced.

Currently there are the first drugs in clinical trials that have a de-methylating effect. Experiments in cell culture indicate that the effectiveness of chemotherapy can be improved by these so-called DNA-de-methylating drugs. “We suspect that CT45 plays a major role in this because it is one of the most abundant proteins in the tumor induced by the drug. This gives us hope that patients who do not have the protein in their tumor could still benefit from combination chemotherapy," says Dr. Marion Curtis, a postdoctoral fellow in the Lengyel laboratory and the last author of the study.

Blessing in disguise

The researchers have made great progress in understanding CT45’s function. This gives hope for the development of new and more targeted therapeutic approaches. "We have evidence that tumor-specific expression of CT45 stimulates the patient's immune system to fight the cancer, as it would be the case with a virus or bacterial-infected cell. "Our long-term goal is to find new ways to improve patient outcomes based on these exciting new insights," summarizes Prof. Dr. Lengyel.

Wissenschaftliche Ansprechpartner:

Prof. Dr. Matthias Mann
Proteomics and Signal Transduction
Max Planck Institute of Biochemistry
Am Klopferspitz 18
82152 Martinsried/Munich
Germany
E-mail: mmann@biochem.mpg.de
http://www.biochem.mpg.de/en/rd/mann

Originalpublikation:

Original publication:
F. Coscia, E. Lengyel, J. Duraiswamy, B. Ashcroft, M. Bassani-Sternberg, M. Wierer, A. Johnson, K. Wroblewski, A. Montag, S. D. Yamada, B. López-Méndez, J. Nilsson, A. Mund, M. Mann, and M. Curtis: Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer, Cell, September 2018

Weitere Informationen:

http://www.biochem.mpg.de/en/20180920-coscia-mann

Dr. Christiane Menzfeld | Max-Planck-Institut für Biochemie

More articles from Life Sciences:

nachricht Exciting Plant Vacuoles
14.06.2019 | Julius-Maximilians-Universität Würzburg

nachricht A microscopic topographic map of cellular function
13.06.2019 | University of Missouri-Columbia

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: MPSD team discovers light-induced ferroelectricity in strontium titanate

Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.

Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...

Im Focus: Determining the Earth’s gravity field more accurately than ever before

Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.

The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...

Im Focus: Tube anemone has the largest animal mitochondrial genome ever sequenced

Discovery by Brazilian and US researchers could change the classification of two species, which appear more akin to jellyfish than was thought.

The tube anemone Isarachnanthus nocturnus is only 15 cm long but has the largest mitochondrial genome of any animal sequenced to date, with 80,923 base pairs....

Im Focus: Tiny light box opens new doors into the nanoworld

Researchers at Chalmers University of Technology, Sweden, have discovered a completely new way of capturing, amplifying and linking light to matter at the nanolevel. Using a tiny box, built from stacked atomically thin material, they have succeeded in creating a type of feedback loop in which light and matter become one. The discovery, which was recently published in Nature Nanotechnology, opens up new possibilities in the world of nanophotonics.

Photonics is concerned with various means of using light. Fibre-optic communication is an example of photonics, as is the technology behind photodetectors and...

Im Focus: Cost-effective and individualized advanced electronic packaging in small batches now available

Fraunhofer IZM is joining the EUROPRACTICE IC Service platform. Together, the partners are making fan-out wafer level packaging (FOWLP) for electronic devices available and affordable even in small batches – and thus of interest to research institutes, universities, and SMEs. Costs can be significantly reduced by up to ten customers implementing individual fan-out wafer level packaging for their ICs or other components on a multi-project wafer. The target group includes any organization that does not produce in large quantities, but requires prototypes.

Research always means trying things out and daring to do new things. Research institutes, universities, and SMEs do not produce in large batches, but rather...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Concert of magnetic moments

14.06.2019 | Information Technology

Materials informatics reveals new class of super-hard alloys

14.06.2019 | Materials Sciences

New imaging modality targets cholesterol in arterial plaque

14.06.2019 | Medical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>